In a clinical study in adults with mild-to-moderate asthma, comparable efficacy (as measured by change from baseline FEVInhalation of 0.04 mg of ipratropium from a metered dose aerosol causes bronchodilation, the maximal effect is seen after 30–60 minutes, with a duration of 4 hours. All doses of active treatment produced a significantly greater degree of bronchodilation (as measured by percent change from pre-dose mean forced expiratory volume (FEV) than placebo, and there were no significant differences between any of the active treatment arms.
Only five patients, 65 years of age and older, were treated with levosalbutamol sulphate inhalation solution in a 4-week clinical study (n = 2 for 0.63 mg and n = 3 for 1.25 mg). It should be used with caution in these patient populations.Serious adverse reactions include paradoxical bronchospasm, cardiovascular effects, immediate hypersensitivity reactions, and hypokalaemia.Adverse reactions reported (≥2% of patients) in a 4-week, controlled clinical trial in adults and adolescents aged12 years and older were allergic reactions, flu syndrome, chills, chest pain, accidental injury, pain, back pain, tachycardia, migraine, dyspepsia, leg cramps, dizziness, hypertonia, nervousness, tremor, anxiety, increased cough, viral infection, rhinitis, sinusitis and turbinate oedema.In the clinical trials, a slightly greater number of serious adverse events, discontinuations due to adverse events, and clinically significant ECG changes were reported in patients who received levosalbutamol sulphate inhalation solution 1.25 mg compared with the other active treatment groups.Most frequently reported adverse reactions (≥2% in any treatment group) and those reported more frequently than in placebo during the double-blind period (6 to 11 years old) were abdominal pain, accidental injury, asthenia, fever, headache, pain, viral infection, diarrhoea, lymphadenopathy, myalgia, asthma, pharyngitis, eczema, rash, urticaria and otitis media.The following adverse reactions, considered potentially related to levosalbutamol sulphate inhalation solution, occurred in less than 2% of the 292 subjects who received levosalbutamol sulphate inhalation solution and more frequently than in patients who received placebo in any clinical trial – ECG abnormal, ECG change, hypertension, hypotension, syncope, diarrhoea, dry mouth, dry throat, dyspepsia, gastroenteritis, nausea, lymphadenopathy, leg cramps, myalgia, anxiety, hyperaesthesia of the hand, insomnia, paraesthesia, tremor, eye itch.In addition to the adverse reactions reported in clinical trials, the following adverse reactions have been observed in post-approval use of levosalbutamol sulphate inhalation solution. The major part of the radio labelled dose is excreted via the kidneys.Although there have been no carcinogenesis studies with levosalbutamol hydrochloride, racemic albuterol sulphate has been evaluated for its carcinogenic potential. The primary route of elimination of albuterol sulphate enantiomers is through renal excretion (80–100%) of either the parent compound or the primary metabolite. Levosalbutamol sulphate inhalation solution has not been approved for the management of preterm labour. This may cause serious side effects. Other drugs may interact with budesonide, including prescription and over-the-counter medicines, Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Pulmicort only for the indication prescribed.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Copyright 1996-2020 Cerner Multum, Inc. You may report side effects to FDA at 1-800-FDA-1088.Sometimes it is not safe to use certain medications at the same time.

In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression. As with all sympathomimetic medications, cardiac arrest and even death may be associated with the abuse of levosalbutamol sulphate inhalation solution.Treatment consists of discontinuation of levosalbutamol sulphate inhalation solution together with appropriate symptomatic therapy. Albuterol is a fast-acting rescue medication to relax airway smooth muscle and relieve symptoms such as coughing, wheezing, chest tightness, shortness of breath. The Flexhaler device has a dose counter that shows how many doses are left inside. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and levosalbutamol sulphate inhalation solution.Levosalbutamol sulphate inhalation solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of levosalbutamol sulphate on the vascular system may be potentiated.

The elimination of ipratropium bromide is biphasic.
The benefit to risk ratio when levosalbutamol is administered for tocolysis has not been established. It has a molecular weight of 430.4 and the empirical formula is CThe drug compatibility (physical and chemical), efficacy, and safety of levalbuterol inhalation solution when mixed with other drugs in a nebulizer have not been established. Pulmicort contains budesonide, a corticosteroid that prevents the release of substances in the body that cause inflammation.. Pulmicort is used to prevent asthma attacks.. Pulmicort Flexhaler is for use in adults and children at least 6 years old.. Pulmicort Respules are for use in children 12 months to 8 years old.. Talk with your doctor if any of your asthma medications do not seem to work as well in treating or preventing asthma attacks.If you also use an oral steroid medication, do not stop using the steroid suddenly or you may have unpleasant withdrawal symptoms. It has a molecular weight of 337.39 g/mol and the empirical formula is CIpratropium bromide is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo -octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8methyl-8-(1-methylethyl)-bromide, a synthetic quaternary ammonium compound, chemically related to atropine. Lebanon Drugs Public Price List - 24/10/2018, is an economic publication that is issued by Ministry of Public Health, containing Daily data.